Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
Revenue of Kezar Life Sciences, Inc. (KZR)
Revenue in 2023 (TTM): $7 M
According to Kezar Life Sciences, Inc.'s latest financial reports the company's current revenue (TTM) is $7 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Kezar Life Sciences, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $7 M | $5.93 M | $-99,254,000 | $-101,870,000 | $-101,870,000 |
| 2022 | $ | $-1,022,999 | $-66,110,000 | $-68,239,000 | $-65,316,000 |
| 2021 | $ | $-1,510,000 | $-52,961,000 | $-54,630,000 | $-53,279,000 |
| 2020 | $ | $-1,544,000 | $-40,256,000 | $-41,742,000 | $-38,990,000 |
| 2019 | $ | $-1,301,000 | $-34,421,000 | $-35,087,000 | $-31,531,000 |
| 2018 | $ | $-690,000 | $-22,477,000 | $-23,167,000 | $-23,167,000 |
| 2017 | $ | $-175,000 | $-8,342,000 | $-8,517,000 | $-8,517,000 |
| 2016 | $ | $-154,000 | $-8,836,000 | $-8,990,000 | $-8,990,000 |